Genmab — September 2020
-
ESMO: Janssen’s anti-EGFR combo tackles lung cancer ahead of phase 3 Tagrisso showdown https://www.fiercebiotech.com/biotech/esmo-janssen-s-anti-egfr-combo-tackles-lung-cancer-ahead-phase-3-tagrisso-showdown
-
"The treatment beat back cancer in 20 newly diagnosed, never-before-treated patients, shrinking tumors in all of them. And in 45 patients whose disease had worsened despite taking Tagrisso, J&J’s treatment curbed tumor growth in 60% of them and shrank tumors in 36% of them. One patient had a complete response, meaning the drug eliminated all signs of cancer".
-
Tak transalp og Pensionist:-)
-
-
-
Could be RA. Has been discussed before. I think Janssen has an unused IND for dara in RA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932888/
-
https://twitter.com/TiansterZhang/status/1308023977483227137 Amgen showing bispecific CD3x PSMA , like JNJ-63898081
-
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin
innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at
ESMO Virtual Congress 2020 -
The results of the tisotumab vedotin phase 2 clinical trial are encouraging as they demonstrate clinically meaningful, durable responses with a manageable side effect profile
-
-
thanks E L
-
der var ikke forventet mere for tiso
-
nogen der har nogen bud på hvor værdifuldt tiso i cervical cancer kan blive?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind